No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
72 |
4. Check minimum number of eventsNone |
72 |
5. Include endpointsNone |
72 |
6. Filter based on genotype QC (FinnGen only) |
62 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Rhabdomyosarcoma, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Solid cancers
- Malignant neoplasm
- Malignant neoplasm
- Solid cancers, including Hilmo
- Malignant neoplasm, wide definition
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 62 | 30 | 32 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 43.56 | 48.04 | 39.37 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 66
- Matched controls
- 660
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
130
Kela drug reimbursment
Malignant tumour
+∞
50.7
42
*
A03FA01
ATC
metoclopramide; systemic, rectal
16.2
29.5
35
43
H02AB02
ATC
dexamethasone; systemic
104.6
25.0
26
*
N02AA05
ATC
oxycodone; systemic
14.5
24.3
28
32
A04AA01
ATC
ondansetron; systemic, rectal
52.4
24.0
28
9
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
23.3
21
*
L03AA02
ATC
filgrastim; parenteral
261.3
19.7
19
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
36.6
19.0
24
10
L03AA13
ATC
pegfilgrastim; parenteral
242.5
18.5
18
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
121.2
17.5
18
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
17.4
16
*
WW500
NOMESCO Finland
Blood transfusion
112.2
16.4
17
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
16.3
15
*
R4110
NOMESCO Finland
Physiotherapy
7.4
15.3
38
102
JN4BD
NOMESCO Finland
Extensive body CT
26.0
13.9
19
10
XW000
NOMESCO Finland
Bone marrow biopsy
87.2
13.2
14
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
12.9
12
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
12.9
12
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
15.6
12.7
21
19
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.8
12.6
47
177
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
11.8
11
*
C49.04
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the head, face and neck rhabdomyosarcoma
+∞
11.8
11
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
53.0
11.4
13
*
Z51.5
ICD-10 Finland
Palliative care
23.7
10.9
15
8
159
Kela drug reimbursment
Pazopanib
+∞
10.7
10
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
10.7
10
*
ZXD10
NOMESCO Finland
Scheduled procedure
5.1
9.9
39
146
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
116.0
9.7
10
*
WZC00
NOMESCO Finland
Treatment plan or consultation
5.0
9.7
36
128
C49.54
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the pelvis rhabdomyosarcoma
+∞
9.6
9
*
C49.39
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the thorax other or unspecified tumor
+∞
9.6
9
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
9.6
9
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
9.6
9
*
C49.24
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of lower extremity including hip rhabdomyosarcoma
+∞
9.6
9
*
NFR30
NOMESCO Finland
Extended excision of soft tissue tumour of hip or thigh
+∞
9.6
9
*
A04AD12
ATC
aprepitant; systemic
+∞
9.6
9
*
GD1AD
NOMESCO Finland
Thorax CT examination
12.3
9.5
17
18
ZXE20
NOMESCO Finland
More than three and less than five hours
6.3
9.3
19
40
ZXA00
NOMESCO Finland
Right side
4.9
8.8
27
81
D48.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Connective and other soft tissue
32.4
8.8
11
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.0
8.6
25
72
343
Kela drug reimbursment
Pazopanib
+∞
8.5
8
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
8.5
8
*
QX3AT
NOMESCO Finland
Ultrasound guided biopsy of subcutaneous tissue
+∞
8.5
8
*
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
+∞
8.5
8
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
8.5
8
*
WX408
NOMESCO Finland
General anesthesy, balanced
4.7
8.4
28
90
HA1AA
NOMESCO Finland
X-ray mammography
38.6
8.3
10
*
QX3HE
NOMESCO Finland
Ultrsound examination of lesion close to skin
38.6
8.3
10
*
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
29.0
7.8
10
*
JN4AD
NOMESCO Finland
Body CT examination
13.1
7.7
13
12
WX404
NOMESCO Finland
Intravenous generell anesthesy
4.6
7.6
24
73
C49.14
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of upper extremity including shoulder rhabdomyosarcoma
+∞
7.4
7
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.4
7
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
7.4
7
*
115
Kela drug reimbursment
Breast cancer
+∞
7.4
7
*
C49.34
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the thoracic rhabdomyosarcoma
+∞
7.4
7
*
XX3DW
NOMESCO Finland
Time consuming IT work
23.1
7.4
10
5
ZX112
NOMESCO Finland
Subcutaneous
34.1
7.4
9
*
Z2221
NOMESCO Finland
Medical doctor
4.1
7.0
28
101
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
19.3
7.0
10
6
A41.9
ICD-10 Finland
Sepsis, unspecified
11.9
6.9
12
12
ZXE10
NOMESCO Finland
More than one and less than three hours
3.9
6.8
33
136
ZXE00
NOMESCO Finland
One hour or less
3.8
6.6
37
167
D70.82
ICD-10 Finland
Drug-induced neutropenia
77.0
6.5
7
*
3AA13, ,
NOMESCO Finland
+∞
6.3
6
*
Z85.8
ICD-10 Finland
Personal history of malignant neoplasms of other organs and systems
+∞
6.3
6
*
C49.49
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the abdomen other or unspecified tumor
+∞
6.3
6
*
WX1BG
NOMESCO Finland
Total body MRI with high intensity magnet
+∞
6.3
6
*
C48.04
ICD-10 Finland
Malignant tumor of the retroperitoneal space rhabdomyosarcoma
+∞
6.3
6
*
TPH07
NOMESCO Finland
Cathetrisation of artery
6.3
6.1
16
32
B01AB05
ATC
enoxaparin; parenteral
3.8
6.1
25
91
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
30
73
6.70
13.03
13.1
9.6
1.09
1.24
mmol/l
1.50
30
68
37
128
5.30
10.45
5.2
2.1
—
—
—
0
0
17
17
13.02
9.74
4.8
3.5
3.40
3.43
g/l
0.02
17
17
17
22
10.00
8.55
5.9
3.8
90.94
86.45
%
0.26
17
22
16
19
10.72
8.41
5.4
2.6
247.37
166.53
%
1.69
16
19
37
147
4.45
8.36
6.6
3.1
0.10
0.32
e6/l
1.50
30
103
45
219
4.32
7.42
5.6
2.6
—
—
estimate
—
0
0
22
67
4.43
6.88
1.8
1.6
—
—
—
0
0
21
64
4.35
6.53
1.9
1.7
—
—
—
0
0
20
62
4.19
6.05
25.0
17.7
25.62
24.34
mmol/l
0.80
20
62
17
47
4.52
5.94
1.6
1.9
31.25
26.97
u/l
0.53
12
37
24
86
3.81
5.93
1.9
1.7
—
—
—
0
0
25
93
3.72
5.84
6.7
3.3
3.21
1.52
e6/l
0.53
14
41
24
89
3.67
5.61
7.0
3.3
2.50
4.11
e6/l
0.28
12
38
46
259
3.56
5.48
21.4
8.7
1.21
1.22
mmol/l
0.14
40
233
22
82
3.52
5.04
10.6
2.2
2.50
2.44
mmol/l
1.65
22
70
19
66
3.64
4.82
3.3
2.9
20.22
24.07
%
0.47
19
61
7
5
15.41
4.68
2.4
2.6
13.29
8.40
%
—
7
5
20
74
3.44
4.60
3.3
2.9
10.32
13.21
umol/l
1.17
20
68
6
8
8.10
3.12
1.5
1.3
—
—
—
0
0
11
32
3.91
3.07
1.4
1.4
—
—
—
0
0
13
47
3.20
3.02
10.1
13.6
111.23
122.60
g/l
1.06
13
47
6
9
7.19
2.93
1.2
1.1
—
—
—
0
0
6
9
7.19
2.93
2.8
1.4
15.87
16.68
%
—
6
9
11
35
3.56
2.80
24.2
17.9
95.73
92.91
%
1.03
11
35
8
19
4.64
2.78
1.4
1.5
—
—
—
0
0
6
10
6.47
2.76
1.2
1.2
—
—
—
0
0
12
42
3.26
2.73
3.7
3.1
—
—
—
0
0
19
95
2.40
2.41
2.0
3.2
151.92
220.70
ng/l
0.16
12
66
6
13
4.96
2.32
1.2
1.3
—
—
—
0
0
6
13
4.96
2.32
1.3
1.4
—
—
—
0
0
5
9
5.90
2.25
1.4
2.1
—
—
—
0
0
12
53
2.55
1.94
37.3
6.4
24.75
23.48
mmol/l
1.01
12
53
8
28
3.11
1.93
1.3
1.5
—
—
—
0
0
6
17
3.77
1.88
3.0
1.4
21.00
70.85
u/ml
—
6
17
5
13
4.07
1.75
1.2
1.9
—
—
—
0
0
6
19
3.36
1.70
1.5
1.8
—
—
—
0
0
6
19
3.36
1.70
1.5
1.9
—
—
—
0
0
5
14
3.77
1.64
3.0
1.3
127.20
131.13
g/l
—
5
8
5
15
3.51
1.55
1.8
1.5
—
—
—
0
0
5
15
3.51
1.55
1.8
1.5
—
—
—
0
0
5
18
2.92
1.31
1.4
1.6
—
—
—
0
0
5
22
2.37
1.05
1.6
2.4
—
—
—
0
0
6
30
2.10
0.89
5.0
8.1
63.43
45.39
%
—
6
30
53
471
1.64
0.79
71.1
16.0
14.23
13.46
%
3.62
53
466
5
24
2.17
0.76
21.0
5.5
1.26
1.24
mmol/l
—
5
17
5
27
1.92
0.70
51.0
9.2
2.12
1.54
%
—
5
27
34
283
1.42
0.65
5.8
3.6
0.00
0.00
estimate
—
9
54
59
548
1.72
0.65
43.9
12.4
33.19
22.99
mg/l
1.38
53
428
34
287
1.38
0.58
6.0
3.6
0.00
0.00
estimate
—
8
52
52
475
1.45
0.52
37.0
11.3
88.87
84.34
ml/min/173m2
0.55
45
423
5
82
0.58
0.49
1.4
2.4
—
—
—
0
0
33
283
1.33
0.49
5.9
3.7
0.00
0.00
estimate
—
9
53
0
15
0.00
0.42
0.0
1.3
—
—
—
0
0
5
36
1.42
0.39
1.8
1.3
—
—
—
0
0
59
605
0.77
0.31
78.6
19.9
37.16
40.81
%
5.89
59
599
59
605
0.77
0.31
73.2
19.2
122.98
136.47
g/l
6.97
59
599
59
604
0.78
0.30
70.6
19.0
90.23
89.34
fl
0.63
59
598
9
72
1.29
0.27
1.1
1.5
—
—
—
0
0
56
536
1.30
0.24
57.1
16.1
138.61
139.68
mmol/l
2.38
56
526
10
79
1.31
0.24
1.9
1.8
1.56
1.33
%
—
10
70
17
145
1.23
0.23
1.5
1.7
—
—
—
0
0
56
537
1.28
0.23
57.2
16.1
3.90
3.99
mmol/l
1.83
56
526
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
46.99
—
0
12
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
23
207
1.17
0.18
2.2
2.0
98.81
100.61
pmol/l
0.06
16
108
16
141
1.18
0.15
4.8
3.3
0.00
0.00
estimate
—
8
50
7
88
0.77
0.15
1.3
2.6
—
—
—
0
0
58
562
1.26
0.15
53.5
14.9
70.98
74.81
umol/l
0.53
58
551
38
399
0.89
0.13
3.1
3.3
—
—
—
0
0
15
139
1.10
0.06
3.3
2.2
65.47
94.65
u/l
0.38
15
125
16
153
1.06
0.01
5.0
3.0
0.00
0.00
estimate
—
6
42
21
206
1.03
0.00
4.1
3.5
0.00
0.00
estimate
—
7
42
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
1003.00
—
0
5
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
1.70
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
56
0.88
-0.00
4.6
6.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.3
—
12.96
—
0
7
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_RHABDOMYOSARCOMA_WIDE – Rhabdomyosarcoma, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).